Streetwise Reports (08/04/2026)
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its EngageWell partnership after an initial virtual-care pilot connected more than 400 underserved New Yorkers with physician-led care. Streetwise Reports (08/04/2026)
BioLargo Inc. (BLGO:OTCQX) announces the processing of more than 2 million gallons of PFAS-contaminated water using its patented Aqueous Electrostatic Concentrator (AEC) technology. Find out why one technical analyst likes BLGO's business model. Streetwise Reports (08/03/2026)
Evommune Inc. (EVMN:NYSE) dosed its first patient in a Phase 2b trial of EVO756, an oral migraine prevention drug targeting the MRGPRX2 receptor. Streetwise Reports (08/03/2026)
Karyopharm Therapeutics Inc. (KPTI:NASDAQ) prepares an FDA filing for selinexor plus ruxolitinib after Phase 3 results, targeting the first approved combination therapy for myelofibrosis. Streetwise Reports (08/03/2026)
Sarepta Therapeutics Inc. (SRPT:NASDAQ) granted CEO Michael Severino options for 2,224,342 shares and 756,104 RSUs as an inducement award tied to his hiring. Streetwise Reports (08/03/2026)
DarioHealth integrates its digital platform with licensed providers to offer end-to-end GLP-1 support. See how the new program targets employers and health plans in a growing market. Streetwise Reports (08/03/2026)
DarioHealth Corp. (NASDAQ: DRIO) introduced its Integrated GLP-1 Program, bringing licensed provider evaluations, FDA-approved GLP-1 prescribing where clinically appropriate and ongoing care into one experience. Streetwise Reports (07/31/2026)
Dyadic International produced two Bundibugyo ebolavirus antigens in about 15 days using its C1 platform and delivered them for preclinical testing amid an active outbreak in Africa. Streetwise Reports (07/31/2026)
Dyadic International Inc. (NASDAQ: DYAI) has rapidly developed and produced recombinant protein antigens targeting Bundibugyo ebolavirus, progressing from receipt of the plasmids to purified proteins in approximately 15 days. As the Ebola outbreak in Africa continues, this achievement highlights the speed and potential of Dyadics C1 protein-production platform. Read why one technical analyst believes DYAIs' stock could be positioned for a bullish move. 
Streetwise Key Charts
